Hetero unveils Favivir 800/200 priced at Rs 2640 per pack

"The launch of 'Favivir 800/2000' is aimed at enhancing patients' adherence to treatment regimen by reducing the number of pills they are required to consume per day," Hetero said.

Published On 2020-09-26 06:45 GMT   |   Update On 2020-09-26 10:41 GMT
Advertisement

New Delhi: Drug firm Hetero on Friday said it has launched a pack of its generic oral antiviral drug-- Favivir 800/200-- for the treatment of mild-to-moderate symptomatic COVID-19 patients in India.

Favivir 800/200 will be available in a pack containing 16 tablets of favipiravir 800 mg and 2 tablets of favipiravir 200 mg priced at Rs 2,640 per pack, Hetero said in a statement.

The higher strength of Favipiravir 800 mg by the company has been approved by the Drug Controller General of India (DCGI). The product will be marketed and distributed by Hetero Healthcare Ltd, it added.
Advertisement
"The launch of 'Favivir 800/200' is aimed at enhancing patients' adherence to treatment regimen by reducing the number of pills they are required to consume per day," Hetero said.
The product will be made available at all retail medical outlets and hospital pharmacies across the country and sold only on prescription, it added.
The drug is being manufactured at the company's facility in India that is approved by global regulatory authorities.
The company had earlier on July 29, launched its generic version of favipiravir in India under the brand name 'Favivir' after getting the nod from the Indian drug regulator.

Read also: Hetero launches Favipiravir under brand name of Favivir in India, prices it at Rs 59 per tablet



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News